AstraZeneca Faces Dual ODAC Scrutiny on Biomarker-Gated Oncology NDAs

AstraZeneca Pharmaceuticals LP enters a pivotal regulatory moment on April 30, 2026, as the FDA's Oncologic Drugs Advisory Committee convenes to evaluate two separate applications in a single session -- a dual review that signals the agency's intensifying focus on biomarker-defined patient populations and the companion diagnostic infrastructure required to support them. For regulatory affairs leads and supply chain planners, committee recommendations on both applications will carry weight well beyond AstraZeneca's portfolio.

The morning session addresses NDA 220359 for camizestrant tablets, proposed for use in combination with a CDK4/6 inhibitor -- palbociclib, ribociclib, or abemaciclib -- in adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who develop an ESR1 mutation during first-line endocrine-based therapy, as detected by an FDA-approved test. The afternoon session turns to sNDA 218197/S-004 for Truqap (capivasertib) tablets, seeking a supplemental indication in combination with abiraterone for adult patients with metastatic hormone-sensitive prostate cancer that is PTEN-deficient, again contingent on detection by an FDA-approved test. Both indications are tightly gated by molecular eligibility criteria, reinforcing a pattern in oncology approvals that demands robust diagnostic alignment before commercial launch.

ODAC recommendations are non-binding, but the FDA generally follows committee guidance. Plant heads and QA directors should note that a positive recommendation for either product will accelerate timelines for process validation, labeling finalization, and distribution network readiness -- particularly given the companion diagnostic dependency that governs patient selection for both indications. Manufacturing and supply readiness planning cannot wait for formal approval letters.

The meeting will be held at the FDA White Oak Campus in Silver Spring, Maryland, with public participation available via an online teleconferencing platform. FDA intends to post background materials no later than two business days before the meeting. A public docket, FDA-2026-N-1867, is open for comment through April 29, 2026, via regulations.gov. Comments submitted by April 16, 2026 will be provided directly to the committee; those received after that date but before the docket closes will be considered by FDA. Source: FDA advisory committee calendar announcement, published April 27, 2026.